[Immunoglobulin decrease accompanying adverse reactions with bucillamine].

S Inokuma; M Sakata; J Ando; S Kobayashi; H Kiyosawa; F Nozawa; K Ito

Home/Archive/PubMed

PubMed · 8235913

[Immunoglobulin decrease accompanying adverse reactions with bucillamine].

S Inokuma·M Sakata·J Ando·S Kobayashi·H Kiyosawa·F Nozawa·K Ito

View original source ↗Export metadata ↓

Abstract

Forty-two RA patients treated with Bucillamine (B) were divided into two groups with (n = 26) and without (n = 16) adverse reactions, and IgG, M, A and total protein concentration x globulin ratio (Ig) before and after B were compared. IgG did not differ before B administration, but was significantly lower in the adverse reactions group after B, and in each group it was significantly lower after B treatment with a much greater decrease demonstrated in the adverse reactions group. IgA before B did not differ either between the two groups or between before and after B administration in the non-adverse reaction group, but was significantly lower only after B in the adverse reaction group. IgM did not differ either before or after B treatment between the two groups, and was significantly lower following B administration in both groups. Ig showed results similar to IgA. In the adverse reaction group, IgG, A, M and Ig recovered following suspension of administration. It is concluded that the adverse reaction brought on by B administration might occur with the decrease in immunoglobulin.

Explore related subjects

Agammaglobulinemia Aged Anti-Inflammatory Agents, Non-Steroidal Arthritis, Rheumatoid Cysteine Female Humans Immunoglobulin A Immunoglobulin G Immunoglobulin M Male Middle Aged English Abstract Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

S Inokuma, M Sakata, J Ando, S Kobayashi, H Kiyosawa, F Nozawa, K Ito. 1993. [Immunoglobulin decrease accompanying adverse reactions with bucillamine].. https://pubmed.ncbi.nlm.nih.gov/8235913/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

BTKbase, mutation database for X-linked agammaglobulinemia (XLA).

X-linked agammaglobulinemia (XLA) is an immunodeficiency caused by mutations in the gene coding for Bruton's agammaglobulinemia tyrosine kinase (BTK). A database (BTKbase) of BTK mutations has been compiled and the recent update lists 225 entries from 189 unrelated families showing 148 unique molecular events. Each patient is given a unique patient identity number (PIN). Information is included regarding the phenotype including symptoms. Mutations in all the five domains of BTK have been noticed to cause the disease, the most common event being missense mutations. The mutations appear almost uniformly throughout the molecule and frequently affect CpG sites forming arginine residues. A decreased frequency of missense mutations was found in the TH, SH3 and upper lobe of the kinase domain. The putative structural implications of all the missense mutations are given in the database.

Agammaglobulinemia↗

PubMed1996

The pleckstrin homology domain: an intriguing multifunctional protein module.

Pleckstrin homology (PH) domains are a family of compact protein modules defined by sequences of roughly 100 amino acids. These domains are common in vertebrate, Drosophila, C. elegans and yeast proteins, suggesting an early origin and fundamental importance to eukaryotic biology. Many enzymes which have important regulatory functions contain PH domains, and mutant forms of several such proteins are implicated in oncogenesis and developmental disorders. Numerous recent studies show that PH domains bind various proteins and inositolphosphates. Here I discuss PH domains in detail and conclude that they form a versatile family of membrane binding and protein localization modules.

Agammaglobulinemia↗

PubMed1996

Prevalence of hepatitis C in patients with primary antibody deficiency.

Concern over sporadic hepatitis C virus (HCV) infection from treatment with contaminated immunoglobulin in patients with immunodeficiency prompted use to screen serum from 44 patients for HCV RNA. We found no evidence of either horizontal or iatrogenic infection in our Clinic, except in two patients known to have received contaminated batches, and in one who had had regular plasma infusions. Thus, common variable immunodeficiency (CVID) patients in England do not have a high incidence of HCV infection despite exposure to various immunoglobulin products. This contrasts with the recently reported high prevalence in similar patients in Italy. Although our data reinforce the impression that both intramuscular and current licensed i.v. preparations in the UK are safe, manufacturers should be encouraged to PCR screen all batches of immunoglobulin for HCV.

Agammaglobulinemia↗